Meet 4 People Who Got The HIV Prevention Jab
A recent article produced by the Bhekisisa Centre for Health Journalism sheds light on the real-world impact of South Africa’s rollout of long-acting injectable HIV pre-exposure prophylaxis (PrEP), Lenacapavir.
The feature profiling four individuals who have received the twice-yearly HIV pr
evention jab highlights how this medical innovation is changing the landscape of HIV prevention. For many, injectable PrEP offers a discreet, convenient, and highly effective alternative to daily oral tablets - eliminating the stigma, inconvenience, and routine pill burden often associated with daily PrEP regimens.
Key takeaways from the individual stories in the article include:
Personalised Experiences: First-hand accounts from recipients detailing their decisions to switch to injectable PrEP and how it fits into their daily lives.
Overcoming Pill Fatigue: How long-acting options make adherence easier, particularly for key populations and young individuals.
Access & Implementation: Insights into the accessibility of the jab across clinics and healthcare facilities as public health programs continue expanding access.
For more insights, read the four women’s full first-hand accounts on one of the resources below:
